Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 11—November 2025

Dispatch

Borrelia afzelii Hepatitis in Patient Treated with Venetoclax and Obinutuzumab, Switzerland

Gioele CapoferriComments to Author , Raphael Battegay, Baptiste Hamelin, Peter M. Keller, Kirsten D. Mertz, and Maja Weisser
Author affiliation: University Hospital Basel, Basel, Switzerland

Main Article

Figure 1

Evolution of cutaneous findings for reported case of early disseminated Lyme borreliosis with multiple erythema migrans and hepatitis in 62-year-old immunosuppressed patient treated with venetoclax and obinutuzumab, Switzerland. A) Oval erythematous rash on the anterior aspect of the right ankle, first lesion to appear (February 20, 2024). B) Right leg with 2 new additional circular/oval patches located on the anterior thigh and anterior knee (March 3, 2024). C–F) Worsening of the exanthemas, with expanding red rash and central clearing (targetoid appearance) on the left leg (C) and onset of red macules on the right arm (D) and the left (E) and right (F) posterolateral trunk (April 9, 2024). G–H) Macules on the décolleté (G) and evolution of cutaneous findings on the right arm, including the appearance of an additional macule (H) (April 27, 2024).

Figure 1. Evolution of cutaneous findings for reported case of early disseminated Lyme borreliosis with multiple erythema migrans and hepatitis in 62-year-old immunosuppressed patient treated with venetoclax and obinutuzumab, Switzerland. A) Oval erythematous rash on the anterior aspect of the right ankle, first lesion to appear (February 20, 2024). B) Right leg with 2 new additional circular/oval patches located on the anterior thigh and anterior knee (March 3, 2024). C–F) Worsening of the exanthemas, with expanding red rash and central clearing (targetoid appearance) on the left leg (C) and onset of red macules on the right arm (D) and the left (E) and right (F) posterolateral trunk (April 9, 2024). G–H) Macules on the décolleté (G) and evolution of cutaneous findings on the right arm, including the appearance of an additional macule (H) (April 27, 2024).

Main Article

Page created: September 18, 2025
Page updated: December 04, 2025
Page reviewed: December 04, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external